There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
In a report issued on September 22, Evan Seigerman from BMO Capital maintained a Buy rating on Eli Lilly & Co, with a price target of $633.00. The company’s shares closed last Friday at $550.54.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $587.71, which is a 7.1% upside from current levels. In a report issued on September 11, DBS also maintained a Buy rating on the stock with a $615.00 price target.
See today’s best-performing stocks on TipRanks >>
Centessa Pharmaceuticals (CNTA)
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Centessa Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Friday at $6.08.
According to TipRanks.com, Biliouris is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Centessa Pharmaceuticals with a $9.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- BCBSM modifying weight loss drug coverage to require ‘lifestyle modifications’
- Eli Lilly, Boehringer: FDA approves Jardiance for treatment of kidney disease
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks
- Scinai Immunotherapeutics announces results from preclinical NanoAbs study
